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ABSTRACT 
Objective: Focus of the study was to formulate Design expert Software assisted floating tablet of Bisoprolol Fumarate. Bisoprolol Fumarate is a Beta 
adrenergic blocking agent, used to treat cardiac diseases favorable characters to be formulated as sustained release Gastro retentive floating tablets.  
Methods: Floating Tablets of Bisoprolol Fumarate were prepared by using polymers such as Polyox N 12 K and Carbapol 940 P. Formulations were 
prepared by using direct compression method and evaluated for various parameters like Hradness, thickness, weight variations, Floating lag time 
Total floating time,% drug release and Stability Study etc.  
Results: FTIR spectroscopic study indicates no drug-excipients interaction in the prepared formulations. Hardness or crushing strength of the 
tablets of all the formulation was found between 5.8 and 6.5 kg/cm2. Floating lag time of all batches is in range of 1.18±2.0 to 2.43±1.6 (minutes). All 
other parameters of all batches are within an acceptable range. The polymer Carbopol 940 P had the significant negative effect of on the floating lag 
times. The In vitro dissolution profiles of optimized A3 Floating formulation of Bisoprolol Fumarate were found to sustain drug release 99.25 % up 
to 12 h with floating lag time of 1.45 min; Designed formulation was stable after Stability study. Optimization study was carried out by using 
32 factorial designs to fabricate formulations.  
Conclusion: It can be conclude that reproducible results of various parameters in this developed formulation can easily scale up. Furthermore 
designed formulation will be very effective for controlling blood pressure.  
Keywords: Software Supported, Bisoprolol Fumarate, Carbapol 940 P, Floating, Direct compression, Floating lag time, Characterization 
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INTRODUCTION 
Over the past few decades, gastric retention has received immense 
popularity in segment of oral drug delivery [1]. Numerous 
Gastroretentive drug delivery systems (GRDDS) have been designed 
to retain drug in the gastric region for prolonged time2 and release 
incorporated drug [2]. And thereby enable sustained and prolonged 
input of the drug to the upper part of the GIT thus leading its optimal 
bioavailability [3]. 
Reported techniques for fabrication of GRDDS are Floating [4-7]., 
Sedimentation [8-11]., Mucoadhesion [12, 13]., Swelling and 
expanding system [14]., modified shape [15]. etc. Techniques which 
shown clinical evidence for prolonged gastric residence time is 
floating, swelling and Mucoadhesion [16, 17]. 
Floating dosage drug delivery system (FDDS) have the sufficient 
buoyancy to float over the gastric contents for a longer time and 
hence it increases bioavailability of drugs which are primly 
absorbed in stomach [18-23]. 
Mucoadhesive system is capable to adhere mucous membrane that 
prevents their passage through the pylorus and the dosage forms 
are retained in the stomach for a longer period of time [24-26]. 
Hypertension it is defined as abnormally high blood pressure (more 
than 120/80 mm of Hg) in the arteries. It is generally symptoms less, 
but increases the risk of various other CVS diseases like Stroke, 
Heart Attack, and non-CVS diseases like renal damage, end-stage 
renal failure [27]. 
Moreover Bisoprolol fumarate ((RS)-1-{4-[(2-isopropoxyethoxy) 
methyl] phenoxy}-3-(Isopropylamino) propan-2-ol) is a beta 
adrenergic blocking agent, used to treat cardiac disease [28]. For a 
drug that have absorption window in the stomach, prolonging the 
gastric residence time may significantly enhance the extent of its 
absorption [28, 29]. 
So aim of present research work effervescent approach based 
Floating tablets of Bisoprolol were fabricated by using various 
polymers such as Polyox N 12 K and Carbapol 940 P with the help of 
Design expert Software. 
MATERIALS AND METHODS 
Materials  
Bisoprolol Fumarate was obtained as a gift sample from Mehta API 
Pvt. Ltd. Tarapur Biosar, India. Polyethylene oxide (Polyox 12 K) was 
gifts from Colorcon Asia Pvt. Ltd. Goa, India. Carbopol 940P, Sodium 
Bicarbonate, Citric Acid,PVP K-30,Talc, Magnesium stearate, 
Dicalcium Phosphate were purchased from Research Lab Fine Chem. 
Ltd. Mumbai India. 
Methods 
Drug–excipient compatibility 
The Infrared Spectra of pure Bisoprolol Fumarate, optimized 
formulations were recorded between 600 and 4000 cm-1 by FT-IR 
Spectrometer using KBr pellet technique to find out any possible 
drug-excipient interaction. 
Fabrication of floating tablets of bisoprolol fumarate 
All the floating tablets were fabricated by using the direct 
compression technique. Drug and Polyox N 12 K,Carbopol 940, PVP 
K-30 and Dicalcium Phosphate were blended homogeneously with 
the help of mortar. Blended mixture was passed through Sieve 60, 
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finally Sodium bicarbonate and magnesium stearate,talc was added 
and blended. The homogeneously blended mixture was compressed. 
The final blend was then compressed into tablets on a 9-station 
rotary tablet machine (Rimek Mini Press–II, Karnavati, 
Ahemadabad,India) using 9-mm round plain punches. The detailed 
composition of formulations is presented in table 3 [28, 29]. 
Optimization of the formulation parameters and the processing 
Concentrations of polyoxyethylene oxide  polyox N 12 K (X1) and 
concentration Carbopol 940 P (X2) were selected as independent 
variables, whereas gastro retentive parameters like  floating  lag 
time (Y1) and % Dug release  at 10 h (Y2) were selected as 
dependent  variables as shown in table 1 and 2 [30]. 
 
Table 1: Layout of batches by 32 full factorial designs 
Batch No. X1 X2 
A1 -1 -1 
A2 -1 0 
A3 -1 +1 
A4 0 -1 
A5 0 0 
A6 0 +1 
A7 +1 -1 
A8 +1 0 
A9 +1 +1 
 
Table 2: Translation of coded value in an actual unit 
Coded value Polyox N12 K (X1) Carbopol 940 P(X2) 
-1 70 15 
0 90 20 
+1 110 25 
Characterization floating tablets of bisoprolol fumarate 
Shape and appearance 
All formulations were prepared well and select randomly and picked 
from each batch examined under the lens for shape and in the 
presence of light for color. 
Tablet hardness 
Hardness of the tablets was measured using a Monsanto hardness tester. 
The hardness expressed in kg/cm2. For each batch three tablets were 
tested. This tester applies force to the tablet diametrically [31].  
Thickness 
Five tablets of the formulation were picked randomly and thickness 
was measured individually using a venire caliper. 
Friability 
For each batch, 20 tablets were weighed and placed in the Roche 
friabilator and apparatus was rotated at 25 rpm for 4 min. After 
revolutions, the tablets were de-dusted and weighed again. The 
percentage friability was measured using formula,  
…. (1) 
Where, % F = Friability in percentage W = Initial weight of tablets 
Wt. = Weight of tablets after revolution.  
Friability below 1% was considered acceptable 
Tablet weight variation 
Weight variation was determined as per I. P. Results are expressed 
as mean values±SD. 20 tablets were randomly selected from each 
batch and individually weighed. The average weight and standard 
deviation of 20 tablets was calculated. The batch passes the test for 
weight variation test if not more than two of the individual tablet 
weight deviates from the average weight [31]. 
 
Table 3: Composition of optimization batches 
Ingredients (mg) Formulation batch code 
A1 A2 A3 A4 A5 A6 A7 A8 A9 
Bisoprolol Fumarate 20 20 20 20 20 20 20 20 20 
Polyox N12 K  70 70 70 90 90 90 110 110 110 
Carbopol 940 P 15 20 25 15 20 25 15 20 25 
PVP K-30 10 10 10 10 10 10 10 10 10 
Sodium Bicarbonate 45 45 45 45 45 45 45 45 45 
Citric Acid 15 15 15 15 15 15 15 15 15 
Talc  5 5 5 5 5 5 5 5 5 
Magnesium Stearate 5 5 5 5 5 5 5 5 5 
Dicalcium Phosphate QS QS QS QS QS QS QS QS QS 
Total weight (mg) 260 260 260 260 260 260 260 260 260 
 *All the values are mean±SD of three determinations, QS =Quantity Sufficient 
  
Drug content uniformity  
5 Tablets are weighed and powdered, from it average weight 
equivalent to dose of drug is weighed and added into 100 ml 
volumetric flask; this powder is dissolved in 0.1 N HCl and sonicated 
for 10 min. From the above solution, 1 ml is taken and diluted to 10 
ml with 0.1 N HCl to get concentration of 50 μg/ml. Then this 
solution is analyzed on UV Spectrophotometer using 222.0 nm 
wavelengths. Each sample was analyzed in triplicate. 
In vitro buoyancy study 
The in vitro buoyancy was determined by floating lag time (FLT) and 
total floating time (TFT). The time required for the tablet to rise to 
the surface and float was determined as floating lag time. The tablets 
were placed in a glass beaker, containing 100 ml of 0.1 N HCl as a 
medium, maintained in a water bath at 37±0.5 °C. Floating lag time 
and total floating duration were determined [32].  
Water uptake studies 
For each formulation batch, one tablet was weighed and placed in a 
beaker containing 200 ml of 0.1 N HCl. After each interval the tablet 
was removed from beaker and weighed again up to 12 h. The 
swelling index study was performed in in triplicate and it calculated 
by using following formula.  
(Swelling index (S. I) = {(wt-wo)/wo} ×100 …. (2) 
Where, S. I. = Swelling index 
Wt. = Weight of tablet at time t  
Wo = Weight of tablet before placing in the Beaker [32].  
In vitro drug release studies 
The release rate of Bisoprolol Fumarate from floating‐mucoadhesive 
tablets was determined using USP dissolution testing apparatus II 
(Paddle type). The dissolution test was performed by using 900 ml 
of 0.1N HCl as a dissolution media having pH 1.2 as per USP 
guidelines, at 37±0.5 °C and 75 rpm/min. A sample (1 ml) of the 
solution was withdrawn from the dissolution apparatus hourly for 
12 h, and the sample is replaced with fresh dissolution medium. The 
samples were passed through what man filter paper and the 
absorbance of these solutions was measured at 222 nm [33].  
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Stability study 
Stability studies were carried out at room temperature 40±20 °C and 
75±5% RH for a specific time period up to 3 Mo for selected 
formulations. For stability study, the tablets were sealed in 
Aluminium packaging coated inside with polyethylene. These 
sample containers were placed in Stability chamber and various 
parameters were studied [34].  
RESULTS AND DISCUSSION  
FT-IR studies for drug–excipient compatibility 
FTIR analysis was performed to authenticate the major functional 
groups present in formulation blend. Compatibility studies of pure 
drug Bisoprolol Fumarate with polymers were carried out prior to 
the preparation of tablets. I. R spectra of pure drug Bisoprolol 
Fumarate, and that of with polymers were obtained, which are 
shown in fig. 1 to fig. 2. All the characteristic peaks of Bisoprolol 
fumarate were present in spectra of formulation blend thus 
indicating compatibility between drugs. It shows that there was no 
significant change in the chemical integrity of the drug. 
Physical properties of the compressed floating tablet systems 
Floating tablets of Bisoprolol Fumarate were prepared by direct 
compression method using various polymers such as Polyox N 12 K 
and Carbapol 940 P. The results of the physical characteristics of 
floating tablets are shown in table 4. 
  
 
Fig. 1: FT-IR spectra of bisoprolol fumarate, the IR spectrum of pure drug was found to be similar to the reference standard IR Spectrum of 
Bisoprolol fumarate given in Indian pharmacopoeia 
 
 
Fig. 2: FT-IR spectra of formulation blend 
 
Table 4: Physical properties of the compressed floating tablet systems 
Formulations Hardness (kg/cm2) Thickness (mm) Friability (%) Weight variation (mg) Drug content (%) 
A1 5.9 4.5±0.04 0.52±0.11 260±0.25 98.64±2.45 
A2 5.8 4.5±0.02 0.42±0.01 260±1.25 98.85±1.80 
A3 5.9 4.7±0.08 0.41±0.00 257±1.75 99.05±2.51 
A4 6.0 4.3±0.07 0.50±0.09 261±1.25 98.75±3.66 
A5 6.2 4.2±0.01 0.48±0.07 253±0.25 99.10±1.82 
A6 6.5 4.8±0.09 0.43±0.02 255±2.25 97.95±2.17 
A7 6.3 4.6±0.02 0.41±0.00 256±2.75 99.23±3.20 
A8 6.4 4.4±0.02 0.45±0.04 263±1.75 98.86±2.12 
A9 6.5 4.5±0.06 0.47±0.06 261±2.75 97.73±2.14 
*All the values are mean±SD of three determinations 
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All Formulations were prepared well and select randomly and 
picked from each batch examined under lens for shape and in 
presence of light for color. Tablets showed standard concave 
surfaces with circular shape. Tablets were white in color. 
Thickness of the tablets was measured using calibrated dial 
calipers by picking three tablets randomly from all the batches. 
The physical evaluation of the tablets revealed uniform thickness.  
All the tablets passed the weight variation test, i.e., average 
percentage weight variation was found within the pharmacopoeia 
limits of±10%. Hardness or crushing strength of the tablets of all 
the formulation was found between 5.8 and 6.5 kg/cm. Low 
friability values (below0.41%) across all formulations indicated 
that the tablets possess good mechanical strength. The obtained 
results were found to be well within the approved range (<1%) in 
all the designed formulations. The drug content uniformity was 
examined as per I. P specification. All the batches of tablets were 
found to comply with uniformity of content test. The drug content 
uniformity studies revealed that drug content between 97.73±2.14 
and 99.23±3.20 % is acceptable [35]. 
Effect of independent variables on floating lag time (Y1) 
Floating tablets is usually fabricated in such a way that its density 
becomes low enabling it to float over gastric fluid. One of the crucial 
factor in designing of floating drug delivery is floating lag time. 
Sodium bicarbonate is responsible for the buoyancy of the tablets 
due to the formation of CO2, when it came in contact with SGF pH 
1.2. The observed results of floating lag times [35] and total floating 
time of all formulations are displayed in table 5. Buoyancy study of 
batches A1 to A9 shows good buoyancy characteristics. Total 
floating time of all the formulation was determined. 
 
Table 5: In vitro buoyancy study of optimized batches 
Formulation codes Floating lag time (min) Total FLT hours 
A1 2.30±1.24 >12 
A2 2.43±1.6 >12 
A3 1.45±1.8 >12 
A4 2.24±1.7 >12 
A5 2.1±1.4 >12 
A6 2.14±2.0 >12 
A7 1.20±1.5 >12 
A8 1.20±1.2 >12 
A9 1.18±2.0 >12 
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A: PEO N 12 K (MG)
B: CARBOPOL 940 (MG)
 
Fig. 3: A response surface plot showing effect of concentration 
of independent variables on the floating lag time 
 
To evaluate the effect of independent variables on floating lag time 
design, expert software was used. A quadratic Model model was 
suggested for floating lag time because of the significant p-
value(0.0045). From response surface plot and contour plot is cited in 
fig. 4 and fig. 5. it can be observed that both polymers polyethylene 
Oxide (PEO)(X1) and Carbopol 940 P (X2) have a significant effect on 
floating lag time. Moreover, the effect of the polymer Carbopol 940 P 
had significantnegative effect of on the floating lag times means 
increase Carbopol 940 amount (X2) will be accompanied by significant 
reduction in the floating lag times it might be due to the hydrophilic 
nature of Carbopol 940P produces faster medium penetration rate, 
and thus, shorter time for gel layer formation these findings are 








X1 = A: PEO N 12 K
X2 = B: CARBOPOL 940



































Fig. 4: A counter plot showing relationship between various 
levels of independent variables to gain fixed value of floating 
lag time 
 
Mathematical relationship in the form of polynomial equation for the 
measured response floating lag time was obtained and given in 
equation 3 below. Positive sign of X in the regression equation 
indicated agonistic effect and negative sign of X in the regression 
equation indicated antagonistic effect of independent variables on 
response. 
Final Equation in Terms of Coded Factors: FLT =+2.07-0.43 * A-0.16* 
B+0.21 * A * B-0.41 * A2-0.038 * B2 (3) 
Water uptake study 
The swelling behaviour of of Bisoprolol fumarate floating 
throughout a period of 12 h is graphically illustrated in fig. 6.  
Swelling of tablet excipients particles involves the absorption of a 
liquid resulting in an increase in weight and volume. The swelling 
index of the tablets increases with an increase in the polymer 
concentration, specially and Carbopol 940 P, since the hydration of 
such functional groups leads to solvent penetration inside the 
polymer matrix resulting in polymer network expansion and 
arrangement of the polymer chains. When erosion of polymer 
dominates over water sorption hence the reduction in tablet weight 
occurs because of constant due to constant erosion of matrix [37]. 
The Swelling Index of optimized batches is shown in fig. 5. 
 
Fig. 5: % Swelling index of optimized batches 
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Polyox is a nonionic, highly swelling hydrophilic polymer absorbing 
7 times its initial weight of water. The swelling ability of the tablets 
could be attributed to the existence of hydrophilic moieties on both 
Polyox N 12K and Carbopol 940 P [38, 39]. 
Effect of independent variables on In vitro drug release (Y2) 
Design-Expert was used to determine the degree of effect of each 
polymer on the percent of drug release [40] is cited in fig. 6 and fig. 7 
The In vitro drug release studies of factorial batches were carried 
out using USP Type II dissolution assembly.  
 
 
Fig. 6: % Drug release in graphical presentation: (A1 to A5) 
 
 
Fig. 7: % Drug release in graphical presentation: (A6 toA9) 
 
Mathematical relationship in the form of polynomial equation for the 
measured response (%CDR at 10 h) was obtained and given in the 
equation below 4. 
% DR =+85.75-4.7* A-2.23* B+4.63* A* B …. (4) 
The response surface and contour plots presenting the effects of the 
independent variables on drug release are illustrated in fig. 9 and 10. 
It is clear from these fig. that both polymers decrease the percent of 
drug release. In addition, Eqs. (4) Show that Carbopol 940 P has a 
more pronounced effect on the percent of drug released. This is 
because of hydrophobic characteristics of the Carbopol 940 P. The 
decreased effect of Carbopol at higher amounts could be possibly 
due the saturation of interstitial space between the swollen gel 
particles. Combination of the prolonged gastric residence time and 
sustained drug release is expected to improve therapeutic effect and 
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A: PEO N 12 K (MG)
B: CARBOPOL 940 (MG)  
Fig. 8: A response surface plot showing effect of concentration 








X1 = A: PEO N 12 K
X2 = B: CARBOPOL 940





























Fig. 9: A counterplot of showing the relationship between 
various levels of independent variables to gain fixed value of % 
drug release 
 
Optimization data analysis for the floating mucoadhesive tablets 
Responses observed for nine formulations were fitted to Design 
Expert Software. All values of R2, degree of freedom and % 
coefficient of variance etc were shown in table 6. Results of ANOVA 
in table 6. for the dependent variables demonstrated that the model 
was significant for all the three response variables [41]. 
 
Table 6: Result of ANOVA 
Response model Sum of square Degree of freedom Mean square F value P value R square Ade. precision 
Floating Lag time 2.05 5 0.41 9.89 0.0045 0.8759 9.263 
% Drug release 250.96 3 83.65 3.87 0.0496 0.9636 7.281 
From data given in table 6 it can be concluded that as predicted values agreed well with the experimental values, demonstrating the feasibility of the 
model in the development of floating tablet dosage form. 
 
Table 7: Stability studies of optimized A3 batch 
Parameters Hardness (Kg/cm2) Friability (%) Drug content (%) Floating lag time (min) 
Initial 5.9±2.1 0.41±0.00 99.05±2.51  1.45±1.8 
After storage 5.7±1.8 0.54±0.41 98.65±1.04 2.43±1.2 
 *All the values are mean±SD of three determinations 
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Stability study 
Stability study is carried out on an optimized batch (A3) of 
Bisoprolol fumarate floating tablets. As per table VII the tablet did 
not show any physical changes during the study period, which is 
show in table VII and the drug content was found to be 
98.65±1.04%, On the basis of results of the stability study we 
concluded that Designed formulation was stable after stability study. 
CONCLUSION  
In this study, an optimized novel floating tablets of Bisoprolol 
Fumarate were was successfully prepared by using various 
polymers such as Polyox N 12 K and Carbapol 940 P. Developed 
floating tablet found to be good without chipping, capping 
characteristics. Hardness or crushing strength of the tablets of all 
the formulation was found between 5.8 and 6.5 kg/cm2. Floating lag 
time of all batches are in range of 1.18±2.0 to 2.43±1.6 (minutes). 
The polymer Carbopol 940 P had the significant negative effect of on 
the floating lag times. The In vitro dissolution profiles of optimized 
A3 floating formulation of Bisoprolol Fumarate were found to 
sustain drug release 99.25 % up to 12 h with floating lag time of 1.45 
min. 32full factorial design and optimization technique successfully 
used in the fabrication of these formulations. Furthermore, 
developed formulations were stable after stability study. The 
promising outcomes from the current studies is selected Bisoprolol 
Fumarate floating tablets could be regarded as a promising 
gastroretentive drug delivery system that could improve the 
bioavailability and hence Patient compliance. 
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